TAIYEN BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.3 TWD | +0.73% |
|
0.00% | +0.29% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,960 | 6,500 | 6,540 | 6,640 | 6,490 | 6,840 |
| Enterprise Value (EV) 1 | 3,794 | 4,756 | 4,859 | 4,952 | 4,743 | 5,225 |
| P/E ratio | 13.2 x | 18.9 x | 18 x | 16.9 x | 15.2 x | 22.8 x |
| Yield | 6.04% | 4.62% | 4.13% | 4.52% | 4.62% | 3.51% |
| Capitalization / Revenue | 1.99 x | 2.24 x | 2.09 x | 1.62 x | 1.8 x | 2.01 x |
| EV / Revenue | 1.26 x | 1.64 x | 1.55 x | 1.21 x | 1.31 x | 1.53 x |
| EV / EBITDA | 6.44 x | 8.14 x | 7.58 x | 7 x | 7.54 x | 10.3 x |
| EV / FCF | 115 x | 44.3 x | -98.7 x | 27.4 x | 22.4 x | 32.1 x |
| FCF Yield | 0.87% | 2.26% | -1.01% | 3.65% | 4.46% | 3.12% |
| Price to Book | 0.97 x | 1.06 x | 1.05 x | 1.04 x | 1 x | 1.05 x |
| Nbr of stocks (in thousands) | 200,000 | 200,000 | 200,000 | 200,000 | 200,000 | 200,000 |
| Reference price 2 | 29.80 | 32.50 | 32.70 | 33.20 | 32.45 | 34.20 |
| Announcement Date | 3/28/19 | 3/25/20 | 3/26/21 | 3/21/22 | 5/15/23 | 3/13/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3,001 | 2,907 | 3,130 | 4,096 | 3,614 | 3,409 |
| EBITDA 1 | 588.7 | 584 | 641.4 | 707.8 | 628.7 | 508.9 |
| EBIT 1 | 418.5 | 419.8 | 463.3 | 529.2 | 445 | 321.4 |
| Operating Margin | 13.94% | 14.44% | 14.8% | 12.92% | 12.32% | 9.43% |
| Earnings before Tax (EBT) 1 | 531.6 | 428.5 | 464 | 509.9 | 530.6 | 329.1 |
| Net income 1 | 452.7 | 345.5 | 365.1 | 393.2 | 426.7 | 300.4 |
| Net margin | 15.08% | 11.89% | 11.66% | 9.6% | 11.81% | 8.81% |
| EPS 2 | 2.260 | 1.720 | 1.820 | 1.960 | 2.130 | 1.500 |
| Free Cash Flow 1 | 33.02 | 107.3 | -49.24 | 180.7 | 211.7 | 162.8 |
| FCF margin | 1.1% | 3.69% | -1.57% | 4.41% | 5.86% | 4.78% |
| FCF Conversion (EBITDA) | 5.61% | 18.38% | - | 25.53% | 33.66% | 32% |
| FCF Conversion (Net income) | 7.29% | 31.07% | - | 45.96% | 49.6% | 54.21% |
| Dividend per Share 2 | 1.800 | 1.500 | 1.350 | 1.500 | 1.500 | 1.200 |
| Announcement Date | 3/28/19 | 3/25/20 | 3/26/21 | 3/21/22 | 5/15/23 | 3/13/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 2,166 | 1,744 | 1,681 | 1,688 | 1,747 | 1,615 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 33 | 107 | -49.2 | 181 | 212 | 163 |
| ROE (net income / shareholders' equity) | 7.44% | 5.61% | 5.99% | 6.4% | 6.49% | 3.29% |
| ROA (Net income/ Total Assets) | 3.59% | 3.51% | 3.76% | 4.07% | 3.34% | 2.43% |
| Assets 1 | 12,613 | 9,830 | 9,707 | 9,669 | 12,794 | 12,359 |
| Book Value Per Share 2 | 30.80 | 30.80 | 31.10 | 31.80 | 32.60 | 32.50 |
| Cash Flow per Share 2 | 8.400 | 8.000 | 7.530 | 8.630 | 7.650 | 7.220 |
| Capex 1 | 298 | 283 | 265 | 389 | 246 | 342 |
| Capex / Sales | 9.94% | 9.73% | 8.46% | 9.49% | 6.81% | 10.02% |
| Announcement Date | 3/28/19 | 3/25/20 | 3/26/21 | 3/21/22 | 5/15/23 | 3/13/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +0.29% | 213M | |
| +19.40% | 8.62B | |
| +6.26% | 7.68B | |
| +7.42% | 6.38B | |
| -6.19% | 3.71B | |
| -6.64% | 3.74B | |
| -3.06% | 1.34B | |
| -26.54% | 1.12B | |
| +20.86% | 1.05B | |
| -10.58% | 913M |
- Stock Market
- Equities
- 1737 Stock
- Financials Taiyen Biotech Co., Ltd.
